CLOs on the Move

Metacrine

www.metacrine.com

 
We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.metacrine.com
  • 3985 Sorrento Valley Boulevard Suite C
    San Diego, CA USA 92121
  • Phone: 858.369.7800

Executives

Name Title Contact Details
Catherine Lee
Senior Vice President and General Counsel Profile

Similar Companies

Clinical Trials Services

Clinical Trials Services is a Lancaster, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nura Inc

Nura Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kiniciti

Empowering the industry with the resources, expertise, and capital to help accelerate the advancement and adoption of cell and gene therapies.

Capstan Therapeutics

Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles conjugated with a recombinant protein binder such as monoclonal antibodies (tLNPs) designed to deliver payloads, including mRNA or gene editing tools, that can reprogram specific cell types in vivo. The platform technology has the potential to generate transformative therapies with applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders.

Kronos Bio

Kronos Bio is clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity.